MM-102

Catalog No.S7265 Synonyms: HMTase Inhibitor IX

For research use only.

MM-102 (HMTase Inhibitor IX) is a high-affinity peptidomimetic MLL1 inhibitor with IC50 of 0.4 μM in a cell-free assay.

MM-102 Chemical Structure

CAS No. 1417329-24-8

Selleck's MM-102 has been cited by 11 Publications

4 Customer Reviews

Purity & Quality Control

Choose Selective Histone Methyltransferase Inhibitors

Biological Activity

Description MM-102 (HMTase Inhibitor IX) is a high-affinity peptidomimetic MLL1 inhibitor with IC50 of 0.4 μM in a cell-free assay.
Targets
MLL1 [1]
(Cell-free assay)
0.4 μM
In vitro

MM-102, as a MLL1 mimetic, shows high binding affinities to WDR5 with IC50 of 2.9 nM and Ki of < 1 nM. In the MLL1-AF9 transduced murine cells, MM-102 specifically reduces expression of two critical MLL1 target genes (HoxA9 and Meis-1), which are required for MLL1 mediated leukemogenesis. In addition, MM-102 effectively and selectively inhibits cell growth and induces apoptosis in leukemia cells harboring MLL1 fusion proteins. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Rosetta 2 (DE3) pLysS Mnf2SpVv[3Srb36gZZN{[Xl? NFnkbo5KdmirYnn0bY9vKG:oIF3MUFEh[mmwZHnu[{B1dyCQLYTldo1qdmGuIFjpd{11[WepZXSgW3JFPSB{MzDk[YxmfGmxbjDteZRidnRiKEK0JJRwKDN|NDDy[ZNq\HWnczmgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO|ZXSgbY4hTXOlaHXybYNpcWFiY3;sbUBTd3OndIThJFIhMESHMzmgdGx6e1NiY3XscJMh[nliZnz1c5Jme2OnbnPlJJBwdGG{aYrheIlwdiCjc4PhfUwhU2liPTCwMlAxOSEQvF2u M3zKTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MkW0PFkzLz5{OUK1OFg6OjxxYU6=
Rosetta 2 (DE3) pLysS MmDHSpVv[3Srb36gZZN{[Xl? MlzGTY5pcWKrdHnvckBw\iCPTFyxJIJqdmSrbnegeI8hVi22ZYLtbY5idCCKaYOteIFo\2WmIGfSSFUhOjNiZHXs[ZRqd25ibYX0ZY51KCh{NDD0c{A{OzRicnXzbYR2\XNrIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJGV{[2incnnjbIliKGOxbHmgVo9{\XS2YTCyJEhFTTNrIIDMfZNUKGOnbHzzJIJ6KG[udX;y[ZNk\W6lZTDwc4xiemm8YYTpc44h[XO|YYmsJGlEPTBiPTCwMlAxOjRizszNMi=> M3\UV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MkW0PFkzLz5{OUK1OFg6OjxxYU6=
Rosetta2-(DE3) pLysS NVK5bXc{TnWwY4Tpc44h[XO|YYm= MXK1JIhzew>? MlLDTY5pcWKrdHnvckBw\iCFLYTldo1qdmGuIEWtSmFONVeLTjDw[ZB1cWSnIHLpcoRqdmdidH:gUk11\XKvaX7hcEBJcXNvdHHn[4VlKFeGUkWgLFI1KHSxIEOzOEBz\XOrZIXld{khMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iUn;z[ZR1[TJvKFTFN{kheEy7c2OgZ4VtdHNiYX\0[ZIhPSCqcoOgZpkh\my3b4Lld4NmdmOnIIDvcIFzcXqjdHnvckBie3OjeTygTWM2OCB;IECuNFAzPCEQvF2u MlPzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5MkC1OVUoRjJ5N{KwOVU2RC:jPh?=
MV4-11 M{fST2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 NW[wVlB1PzJiaILz MYTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2YND2xNUBk\WyuczDoZZJjd3KrbnegUWxNNUGINDDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBES0t6LXLhd4VlKGOxbH;ybY1mfHKrYzDhd5NigSxiSVO1NEA:KDJyLkeg{txONg>? M2LjTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{KwOVU2Lz5{N{eyNFU2PTxxYU6=
MV4-11 M3n3UGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 M{e2[VczKGi{cx?= NEntdYNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3WOE0yOSClZXzsd{Bp[XKkb4LpcochVUyOLVHGOEBnfXOrb36gdJJwfGWrbjDh[pRmeiB5MjDodpMh[nliQ1PLPEBie3OjeTygTWM2OCB;IEKwMlch|ryPLh?= MmOzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd3OUiyN|YoRjJ5NUm4NlM3RC:jPh?=
MV4-11 NFi1NFBCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NF\FWoc4KGSjeYO= MX;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2YND2xNUBk\WyuczDoZZJjd3KrbnegUWxNNUGINDDh[pRmeiB5IHThfZMh[nliQ3XscHRqfGW{LVfsc{BtfW2rbnXzZ4VvfCClZXzsJJZq[WKrbHn0fUBCe3OjeTygTWM2OCB;IEK1JO69VS5? NUG5UppPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3NlA2PTVpPkK3O|IxPTV3PD;hQi=>
MV4-11 NXu2cHplSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MXXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2YND2xNUBk\WyuczDoZZJjd3KrbnegUWxNNUGINDDmeZNqd25icILveIVqdiCkeTDD[YxtXGm2ZYKtS4xwKGG|c3H5MEBKSzVyIE2gNlUh|ryPLh?= NVPSb44zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke1PVgzOzZpPkK3OVk5OjN4PD;hQi=>
K562 MYDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NG[yT2o4OiCqcoO= MnTORY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCNNU[yJINmdGy|IHjhdoJwemmwZzDCR3IuSUKOIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3XscEB3cWGkaXzpeJkh[W[2ZYKgO|IhcHK|IHL5JGNEUzhvYnHz[YQh[2:ub4LpcYV1emmlIHHzd4F6NCCLQ{WwJF0hOzdwODFOwG0v MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd{MEW1OUc,Ojd5MkC1OVU9N2F-
K562 NWTmTmdST3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVO3JIRigXN? MmjpS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gT|U3OiClZXzsd{Bi\nSncjC3JIRigXNiYomgUXRUKGG|c3H5MEBKSzVyIE2gN|cvQCEQvF2u NUe4dlJURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke1PVgzOzZpPkK3OVk5OjN4PD;hQi=>
MV4-11 M3TJdmZ2dmO2aX;uJIF{e2G7 MkDkNVAhfU1? MlG4O{Bl[Xm| M1S3ZmlvcGmkaYTpc44hd2ZiTVzMNU1YTFJ3IIDyc5RmcW5vcILveIVqdiCrboTldoFkfGmxbjDpckBpfW2jbjDNWlQuOTFiY3XscJMhcGG{Yn;ybY5oKE2OTD3BSlQh\nW|aX;uJJBzd3SnaX6gZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDNUGwyKGirc4TvcoUhdWW2aInseJJidnOoZYLhd4Uh[WO2aY\peJkh[nlibXXhd5VzcW6pIILl[JVkfGmxbjDpckBJO0t2bXWyJIxmfmWuIHH0JFExKHWPIHHmeIVzKDdiZHH5d{BjgSCZZYP0[ZJvKGKub4SgcYV1cA>? NXvGOml1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke1PVgzOzZpPkK3OVk5OjN4PD;hQi=>
Assay
Methods Test Index PMID
Growth inhibition assay Cell viability 23210835

Protocol (from reference)

Kinase Assay:

[1]

  • In Vitro Histone Methyltransferase (HMT) Assay:

    The HMT assay is performed in 50 mM HEPES pH 7.8, 100 mM NaCl, 1.0 mM EDTA, and 5% glycerol at 22 °C. Each reaction contains 1.5 μCi of the co-factor, 3H-S-adenosylmethionine. H3 10-residue peptide is used as the substrate at 50 μM. Compounds are added at concentrations ranging from 0.125 to 128 μM and incubated with the pre-assembled WDR5/RbBP5/ASH2L complex at a final concentration of 0.5 μM for each protein for 2–5 min. Reactions are initiated by addition of the MLL1 protein at a final concentration of 0.5 μM and allowed to proceed for 30 min before preparing scintillation counting. To count samples, reactions are spotted on separate squares of P81 filter paper and precipitated by submerging in freshly prepared 50 mM sodium bicarbonate buffer with pH 9.0. After washing and drying, samples are vortexed in Ultima Gold scintillation fluid and counted. As a negative control, assays are performed using 0.5 μM MLL1/WDR5/RbBP5/ASH2L complex assembled with the non-interacting mutant, WDR5D107A.

Cell Research:

[1]

  • Cell lines: MV4;11, KOPN8, and K562 cells
  • Concentrations: ~100 μM
  • Incubation Time: 7 days
  • Method:

    MV4;11, KOPN8, and K562 cells are cultured in RPMI 1640 medium (ATCC) supplemented with 10% fetal bovine serum and 100 U/L penicillin-streptomycin and incubated at 37 °C under 5% CO2. Cells are seeded into 12-well plates for suspension at a density of 5 × 105 per well (1 mL) and treated with either vehicle control (DMSO, 0.2%) or MM-102 for 7 days. The medium is changed every 2 days, and compounds are resupplied. The CellTiter-Glo Luminescent Cell Viability Assay kit is used following the manufacturer’s instruction. First, 100 μL of the assay reagent is added into each well, and the content is mixed for 2 min on an orbital shaker to induce cell lysis. After 10 min incubation at room temperature, the luminescence is read on a microplate reader.

  • (Only for Reference)

Solubility (25°C)

In vitro

DMSO 100 mg/mL
(149.29 mM)
Water 100 mg/mL
(149.29 mM)
Ethanol '100 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 669.8
Formula

C35H49F2N7O4

CAS No. 1417329-24-8
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCC(CC)(C(=O)NC(CCCN=C(N)N)C(=O)NC1(CCCC1)C(=O)NC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)NC(=O)C(C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy MM-102 | MM-102 supplier | purchase MM-102 | MM-102 cost | MM-102 manufacturer | order MM-102 | MM-102 distributor